Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

5.3.99.2: Prostaglandin-D synthase

This is an abbreviated version!
For detailed information about Prostaglandin-D synthase, go to the full flat file.

Word Map on EC 5.3.99.2

Reaction

(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
=
(5Z,13E,15S)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate

Synonyms

beta-Trace, Beta-trace protein, betaTP, glutathione dependent prostaglandine D2 synthase, Glutathione-dependent PGD synthetase, glutathione-dependent prostaglandin D2 synthase, Glutathione-independent PGD synthetase, H-PGDS, haematopoietic PGD synthase, haematopoietic prostaglandin D synthase, Hematopoietic prostaglandin D synthase, hematopoietic prostaglandin D2 synthase, HPGDS, Isomerase, prostaglanin R2 D-, L-PGDS, L-prostaglandin D synthase, L-type prostaglandin synthase, lipocalin prostaglandin D synthase, lipocalin type prostaglandin D synthase, lipocalin-prostaglandin D synthase, lipocalin-type PG D synthase, lipocalin-type PGD synthase, lipocalin-type Pgds, lipocalin-type prostaglandin d synthase, lipocalin-type prostaglandin D2 synthase, lipocaline-type prostaglandin D synthase, PGD synthase, PGD-S, PGD2 synthase, PGD2 synthetase, PGDS, PGDS2, PGH-PGD isomerase, PGH2 D-isomerase, Prostaglandin D synthase, Prostaglandin D2 synthase, prostaglandin D2 synthetase, prostaglandin synthase, Prostaglandin-D synthase, Prostaglandin-H2 D-isomerase, Prostaglandin-R-prostaglandin D isomerase, PTGDS

ECTree

     5 Isomerases
         5.3 Intramolecular oxidoreductases
             5.3.99 Other intramolecular oxidoreductases
                5.3.99.2 Prostaglandin-D synthase

Inhibitors

Inhibitors on EC 5.3.99.2 - Prostaglandin-D synthase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1-benzoyl piperazine
-
1-benzoyl piperidine
-
1-benzoyl-4-(methylsulfonyl)piperazine
-
1-phenyl-1-(2-thienyl)methanamine
-
11-hydroxy-DELTA9-tetrahydrocannabinol
-
-
11-nor-9-carboxy-DELTA9-tetrahydrocannabinol
-
-
15-Hydroperoxyarachidonic acid
-
-
2'-methoxy-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl][2,4'-bipyridine]-5-carboxamide
-
2'-oxo-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]-1',2'-dihydro[2,4'-bipyridine]-5-carboxamide
-
2-(2'-benzothiazolyl)-5-styryl-3-(4'-phthalhydrazyl) tetrazolium chloride
-
IC50: 0.0362 mM in presence of EDTA, 0.0981 in presence of Mg2+
2-phenyl-5-(1H-pyrazol-3-yl)-1,3-thiazole
2-phenyl-5-(1H-pyrazol-3-yl)thiazole
3,3',5'-triiodo-L-thyronine
-
0.0093 mM, 50% inhibition
3,3',5-triiodo-L-thyronine
-
0.011 mM, 50% inhibition
3-(1H-indol-4-yl)-N-(3-methoxypropyl)-1,2,4-oxadiazole-5-carboxamide
-
3-(1H-pyrazol-4-yl)pyridine
-
58% inhibition at 0.1 mM
3-(3-cyclopropyl-1H-pyrazol-4-yl)-N-ethyl-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide
-
-
3-(3-cyclopropyl-1H-pyrazol-4-yl)pyridine
-
-
3-acetamido-N-[5-(1H-indol-4-yl)pyridin-3-yl]propanamide
-
3-benzoylpyrrole
-
3-phenyl-5-(1H-pyrazol-3-yl)-1,2-oxazole
-
4-(3-methyl-1H-pyrazol-4-yl)benzonitrile
-
52% inhibition at 0.03 mM
4-(dimethylamino)-N-[5-(1H-indol-4-yl)pyridin-3-yl]butanamide
-
4-(diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl]piperidine
-
-
4-benzhydryloxy-1-[3-(1H-tetrazol-5-yl)-propyl]piperidine
-
HQL-79
4-dibenzo [a,d]cyclohepten-5-ylidene-1-[4-(2H-tetrazol-5-yl)-butyl]-piperidine
4-methyl-2-phenyl-N-(4-sulfamoylphenyl)-1,3-thiazole-5-carboxamide
-
4-[[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino]-2-hydroxybenzoic acid
5-(3-aminophenyl)-N-benzhydrylthiophene-2-carboxamide
-
-
5-(3-cyanophenyl)-N-(diphenylmethyl)thiophene-2-carboxamide
5-(3-hydroxyphenyl)thiophene-2-carboxylic acid
5-amino-4-[[(3'-hydroxybiphenyl-4-yl)carbonyl]amino]-5-oxopentanoic acid
6'-oxo-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]-1',6'-dihydro[2,2'-bipyridine]-5-carboxamide
-
6'-oxo-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]-1',6'-dihydro[2,3'-bipyridine]-5-carboxamide
-
6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]pyridine-3-carboxamide
-
-
6-(3-fluorophenyl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
6-(3-methoxyphenyl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-(3-oxopiperazin-1-yl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-(dimethylamino)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-(morpholin-4-yl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-(piperazin-1-yl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-(piperidin-1-yl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-(pyrrolidin-1-yl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
6-phenoxy-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridine-3-carboxamide
-
ajulemic acid
-
-
all-trans-retinoic acid
-
-
anthralin
i.e. 1,8-dihydroxyanthracen-9(10H)-one
AT-56
-
inhibition of prostaglandin-D synthase, resulting in suppression of prostaglandin D2 production under serum-starved conditions
atovaquone
-
benzophenone
-
bilirubin
-
0.0068 mM, 50% inhibition
Biliverdin
-
0.0053 mM, 50% inhibition
bithionate sodium
-
bromocriptine mesylate
-
candesartan cilextil
-
cannabidiol
-
-
chlorophyllide copper complex sodium salt
linear competitive inhibitor
Cibacron blue
0.00003 mM, 50% inhibition
Cibacron blue 3GA
-
CMB5190724
-
CMB5256165
-
cyclohexyl-phenylketone
-
cyclopentyl-phenylketone
-
DELTA9-tetrahydrocannabinol
-
-
deoxycorticosterone acetate
-
EDJ300520
-
-
-
epirubicin hydrochloride
-
erythrosine sodium
i.e. disodium 2-(2,4,5,7-tetraiodo-6-oxido-3-oxo-3H-xanthen-9-yl)benzoate
Ethacrynic acid
fluorescein
-
haematin
0.00008 mM, 50% inhibition
Hexachlorophene
-
HQL-79
iodoacetamide
-
-
iopanic acid
linear competitive inhibitor, i.e. 2-[(3-amino-2,4,6-triiodophenyl)methyl]butanoic acid
Ketoprofen
i.e. [3-(3-hydroxybut-3-en-2-yl)phenyl](phenyl)methanone
L-thyroxine
-
0.0039 mM, 50% inhibition, noncompetitve inhibition
lapatinib
-
merbromin
-
montelukast sodium
-
N-(1,6-diamino-1-oxohexan-2-yl)-3'-hydroxybiphenyl-4-carboxamide
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-2,3'-dihydroxybiphenyl-4-carboxamide
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-3'-hydroxybiphenyl-3-carboxamide
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-3'-hydroxybiphenyl-4-carboxamide
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-3,3'-dihydroxybiphenyl-4-carboxamide
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-4-(1H-indol-4-yl)benzamide
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-4-(thiophen-2-yl)benzamide
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-5-(3-hydroxyphenyl)-thiophene-2-carboxamide
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-6-(thiophen-2-yl)nicotinamide
N-(1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-3'-hydroxybiphenyl-4-carboxamide
N-(1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-5-(3-hydroxyphenyl)thiophene-2-carboxamide
N-(1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-5-(3-hydroxyphenyl)thiophene-2-carboxamide
N-(1-amino-3-cyclohexyl-1-oxopropan-2-yl)-5-(1H-indol-4-yl)thiophene-2-carboxamide
N-(1-amino-3-methyl-1-oxobutan-2-yl)-3'-hydroxybiphenyl-4-carboxamide
N-(1-amino-4-methyl-1-oxopentan-2-yl)-3'-hydroxybiphenyl-4-carboxamide
N-(1-amino-4-methyl-1-oxopentan-2-yl)-5-(3-hydroxyphenyl)-thiophene-2-carboxamide
N-(2-amino-2-oxoethyl)-5-(3-hydroxyphenyl)thiophene-2-carboxamide
N-(5-fluoro-3-methyl-1H-indol-1-yl)-2-(pyridin-2-yl)pyrimidine-5-carboxamide
-
-
N-(diphenylmethyl)-2-(3-hydroxyphenyl)-1,3-thiazole-4-carboxamide
N-(diphenylmethyl)-2-phenyl-1,3-thiazole-4-carboxamide
N-(diphenylmethyl)-5-(1H-indol-4-yl)thiophene-2-carboxamide
N-(diphenylmethyl)-5-phenylthiophene-2-carboxamide
N-(diphenylmethyl)-5-[3-(hydroxymethyl)phenyl]thiophene-2-carboxamide
N-(diphenylmethyl)biphenyl-4-carboxamide
N-([4-[5-(2-hydroxypropan-2-yl)-1,2,4-oxadiazol-3-yl]phenyl]methyl)-2-phenylpyrimidine-5-carboxamide
-
N-benzhydryl-5-(3-hydroxyphenyl)thiophene-2-carboxamide
-
low micromolar potency in the inhibition of the purified enzyme
N-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
-
-
N-cyclopentyl-3-(3-cyclopropyl-1H-pyrazol-4-yl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide
-
66% inhibition at 10 nM
N-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
-
-
N-methoxy-N-methyl-4-(5-benzoylbenzimidazole-2-yl)-3,5-dimethylpyrrole-2-carboxamide
-
TAS-204, specific H-PGDS inhibitor
N-phenyl-2-thiophene-carboxamide
-
N-[4-(morpholin-4-yl)phenyl]-2-phenoxypyrimidine-5-carboxamide
-
N-[4-methyl-3-({3-[(4-methylpiperazin-1-yl)methyl]benzoyl}amino)phenyl]-3-phenyl-1,2-thiazole-5-carboxamide
N-[4-methyl-3-[([3-[(4-methylpiperazin-1-yl)methyl]phenyl]carbonyl)amino]phenyl]-3-phenylisothiazole-5-carboxamide
-
N-[5-(1H-indol-4-yl)pyridin-3-yl]-2-(1-methyl-1H-imidazol-5-yl)acetamide
-
N-[5-(1H-indol-4-yl)pyridin-3-yl]-2-(1H-tetrazol-1-yl)acetamide
-
N-[5-(1H-indol-4-yl)pyridin-3-yl]-3-(piperidin-1-yl)propanamide
-
N-[5-(1H-indol-4-yl)pyridin-3-yl]-3-(pyridin-3-yl)propanamide
-
N-[5-(1H-indol-4-yl)pyridin-3-yl]-5-oxopyrrolidine-2-carboxamide (incorrect configuration definition!)
-
N-[5-(1H-indol-4-yl)pyridin-3-yl]propanamide
-
Na2SeO3
-
systemic administration of the inhibitor has sleep-reducing potency
nilotinib
-
nisoldipine
-
nocodazole
-
NSC151248
-
oleic acid
-
-
oxfendazole
-
p-hydroxymercuribenzoate
-
-
palmitoleic acid
-
-
pararosaniline pamoate
-
phenyl(thiophen-2-yl)methanone
phenyl-(2-thienyl)-methanol
-
phenyl-(3-thienyl)-methanone
-
prostaglandin E2
-
-
prostaglandin E2-glyceryl ester
-
-
prostaglandin F2alpha
-
-
pyrvinium pamoate
-
retinoic acid
non-competitive
RNAi
-
-
-
sanguinarine sulfate
linear competitive inhibitor
SBFI-26
-
-
Se2+
-
organic selenocompounds have no effect, hexavalent selenium compound is ineffective. The inhibition requires the preincubation of the metal with sulfhydryl compounds such as dithiothreitol, reversal of inhibition by excess amount of dithiothreitol. The rat spleen enzyme is much less inhibited than the rat brain enzyme
SeCl4
sennoside A
-
Sulfobromophthalein
-
Tannic acid
nonlinear competitive inhibitor
telmisartan
-
tranilast
i.e. 2-{[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino}benzoic acid
Tributyltin acetate
0.00009 mM, 50% inhibition
tributyltin bromide
0.00003 mM, 50% inhibition
Tributyltin chloride
0.00001 mM, 50% inhibition
additional information
-